For a patient taking trazodone 150 mg at bedtime, hydroxyzine 25 mg every 6 hours as needed, isosorbide, memantine, metformin, a statin, nitroglycerin, midodrine, entacapone, glucosamine, hyoscyamine, carbidopa‑levodopa, quetiapine 50 mg three times daily with an additional 50 mg PRN, escitalopram, melatonin 3 mg at bedtime, Miralax, vitamin D, and senna, who is experiencing behavioral disturbances and insomnia, what medication adjustments should be recommended?

Medication Adjustments for Behavioral Disturbances and Insomnia

Discontinue trazodone 150 mg at bedtime and replace it with a guideline-recommended agent such as low-dose doxepin (3-6 mg), eszopiclone, or zolpidem for insomnia, while simultaneously reducing the quetiapine regimen and addressing potential medication-induced behavioral symptoms from the complex polypharmacy.

Critical Issues with Current Regimen

Trazodone Must Be Discontinued

The American Academy of Sleep Medicine explicitly recommends against using trazodone for insomnia treatment 1. Despite its widespread off-label use, evidence shows insufficient efficacy data, high discontinuation rates due to side effects (sedation, dizziness, psychomotor impairment), and particular concerns in elderly patients 2. The current 150 mg dose is in the antidepressant range 3, yet the patient is already on escitalopram for depression, making trazodone redundant and potentially harmful.

Melatonin is Ineffective

The patient is taking melatonin 3 mg, which guidelines specifically recommend against for chronic insomnia 1. This should be discontinued as it provides no evidence-based benefit 4.

Quetiapine Dosing is Problematic

The patient receives quetiapine 50 mg TID plus 50 mg TID PRN (potentially 300 mg/day). This atypical antipsychotic is being used off-label for behavioral symptoms, but the dosing pattern suggests poor symptom control. The FDA-approved dosing for bipolar depression is 300 mg once daily at bedtime 5, not divided doses. For behavioral symptoms in dementia (suggested by memantine and galantamine use), quetiapine should be used cautiously and at the lowest effective dose.

Recommended Medication Adjustments

For Insomnia Management

First-line pharmacologic options (choose one based on insomnia pattern):

• Doxepin 3-6 mg at bedtime for sleep maintenance insomnia 1 - preferred in elderly with dementia
• Eszopiclone 2 mg at bedtime for both sleep onset and maintenance 1
• Zolpidem 5 mg at bedtime (lower dose for elderly) for sleep onset and maintenance 1
• Suvorexant 10 mg at bedtime for sleep maintenance 1

Rationale: These agents have AASM guideline support with evidence for efficacy. Doxepin at low doses (3-6 mg) is particularly appropriate given the patient's likely advanced age (on memantine, galantamine suggesting dementia) and has better tolerability than trazodone 6.

For Behavioral Disturbances

Quetiapine adjustment strategy:

1. Consolidate dosing: Convert to once-daily dosing at bedtime, starting at 50-100 mg
2. Titrate based on response: Can increase by 50 mg increments every 2-3 days if needed, maximum 300 mg for behavioral symptoms 5
3. Monitor closely: Elderly patients should start at 25-50 mg with slower titration 5

Critical consideration: The behavioral symptoms may be medication-induced from:

• Anticholinergic burden (hyoscyamine, quetiapine)
• Dopaminergic medications (carbidopa-levodopa, entacapone)
• Polypharmacy interactions

Additional Medication Concerns

Hydroxyzine 25 mg Q6H PRN should be discontinued or severely limited. This antihistamine adds to anticholinergic burden, worsens cognition in dementia patients, and is not recommended for chronic insomnia 1.

Hyoscyamine (anticholinergic) may be contributing to behavioral symptoms and should be reassessed for necessity.

Implementation Algorithm

Week 1-2:

1. Discontinue: Trazodone, melatonin, limit/stop hydroxyzine PRN
2. Start: Doxepin 3 mg at bedtime (or alternative from list above)
3. Consolidate: Quetiapine to 50 mg at bedtime only
4. Monitor: Sleep quality, daytime sedation, behavioral symptoms

Week 3-4:

1. Titrate doxepin to 6 mg if sleep remains poor
2. Adjust quetiapine by 50 mg increments if behaviors persist (max 200-300 mg for this indication)
3. Reassess: Anticholinergic medications (hyoscyamine) - consider discontinuation if contributing to delirium/behaviors

Week 5-6:

1. Optimize doses based on response
2. Consider: If insomnia persists despite medication, evaluate for sleep apnea, restless legs, or medication-induced causes
3. Long-term plan: Attempt to use lowest effective doses; consider non-pharmacologic interventions (sleep hygiene, stimulus control) 4, 7

Critical Safety Considerations

Falls risk: This patient is on midodrine (for orthostatic hypotension), suggesting fall risk. Trazodone causes orthostatic hypotension in 10% of patients 6, making its discontinuation even more urgent. The new sleep agent should be started at the lowest dose.

Parkinson's disease: The presence of carbidopa-levodopa and entacapone suggests Parkinson's disease. Quetiapine is the preferred antipsychotic in PD due to minimal extrapyramidal effects, but dose should remain low. Avoid other antipsychotics.

Cognitive impairment: Memantine and galantamine indicate dementia. Minimize anticholinergic burden aggressively - this alone may improve both sleep and behaviors.

Drug interactions: The patient is on isosorbide and nitroglycerin (nitrates). Ensure no PDE5 inhibitors are added. Monitor for additive hypotensive effects with new sleep medications.

Expected Outcomes

With appropriate medication adjustments, expect:

• Improved sleep quality within 1-2 weeks of starting guideline-recommended agent
• Reduced behavioral symptoms within 2-4 weeks as anticholinergic burden decreases and quetiapine is optimized
• Fewer side effects including less daytime sedation, reduced fall risk, and improved cognition

The 2017 AASM guidelines provide the strongest evidence against trazodone and melatonin while supporting specific alternatives 1. The 2008 guidelines emphasize that when pharmacotherapy is used, it should follow evidence-based sequences and be combined with behavioral interventions when possible 4.